Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

Go back to Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
(NASDAQ: CRNX) Delayed: 84.95 --0 (-0%)
Previous Close $84.95    52 Week High
Open $84.95    52 Week Low
Day High $84.95    P/E N/A 
Day Low $84.95    EPS
Volume 910,230